Reviewed listing: NASDAQ:CRMD · Analysis dated Oct 21, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
CorMedix sells products to combat severe infections. DefenCath is intended to prevent bloodstream infections in certain dialysis patients; additional drugs came with Melinta.
What supports the business?
The company makes money: in the first half of 2026, operations generated around 128.6 million USD.
What could improve?
More patients treated, improved reimbursement, and additional approved uses could strengthen the business. An additional use is being evaluated for Rezzayo.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 7.57 USD, an attractive price is possible, but not yet established. The strong earnings before the reimbursement reduction cannot simply be extrapolated.
What is the main risk?
Declining net prices for DefenCath could sharply reduce profit. The acquisition brings further payment obligations and additional accounting requirements.
What is the overall assessment?
CorMedix sells drugs to prevent and treat serious infections and is profitable. However, reduced reimbursement for DefenCath is weighing on the second half of the year. At 7.57 USD, the stock could become interesting, but sustainable earnings are not yet sufficiently established. Watch.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in